findmyKOL
Clinical trialNCT05607420RecruitingPhase 1/PHASE2Interventional

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

SponsorCellectis S.A.Enrollment80B-cell Non-Hodgkin Lymphoma (B-NHL)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France
  • Hospices Civils de Lyon (hcl) - Centre Hospitalier Lyon-Sud

    Pierre-Bénite, Auvergne Rhone Alpe, France

    Emmanuel Bachy
    Recruiting
  • Centre Hospitalier Universitaire de Montpellier (chu Montpellier) - Hopital Saint-Eloi

    Montpellier, Occitanie, France

    Guillaume Cartron
    Recruiting
  • Assistance Publique-Hopitaux de Paris (ap-Hp) - Hopital Saint-Louis - Centre Integre En Cancerologie

    Paris, Île-de-France Region, France

    Catherine Thieblemont
    Recruiting
  • Centre Hospitalier Universitaire de Nantes (chu de Nantes)-Hotel-Dieu

    Nantes, France

    Thomas Gastinne
    Recruiting
Spain
  • Universidad de Navarra - Clinica Universidad de Navarra (cun) - Pamplona

    Pamplona, Navarre, Spain

    Ana Alfonso
    Recruiting
  • Hospital Universitario Virgen del Rocio (huvr) - Instituto de Biomedicina de Sevilla (ibis)

    Seville, Spain

    Jose Antonio Perez Simon
    Recruiting
United States
  • the University of Chicago Medical Center (ucmc)

    Chicago, Illinois, United States

    Peter Riedell
    Recruiting
  • Harvard Medical School - Massachusetts General Hospital

    Boston, Massachusetts, United States

    Jeremy Abramson
    Recruiting
  • Rutgers Cancer Institute of New Jersey (cinj) - New Brunswick

    New Brunswick, New Jersey, United States

    Matthew Matasar
    Recruiting
  • Sarah Cannon - St. David South Austin Medical Center

    Austin, Texas, United States

    Aravind Ramakrishnan
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CLLS52UCART20x22
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Nov 2022
Primary completion
31 Aug 2027
Completion
31 Aug 2027
Last update posted
24 Aug 2025
Registered enrollment
80
Registry id
NCT05607420
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.